AC5 inhibitor for heart failure

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$205,669.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
1R44HL112512-01
Agency Tracking Number:
R44HL112512
Solicitation Year:
2012
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA11-096
Small Business Information
VASADE BIOSCIENCES, INC.
675 US Highway One, North Brunswick, NJ, 08902-
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
145239112
Principal Investigator
 PATRICIO ABARZUA
 (973) 953-4377
 abarzua@vasadebiosciences.com
Business Contact
 ABARXUA PATRICIO
Phone: (973) 953-4377
Email: abarzua@vasadebiosciences.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Cardiovascular disease is a critical health issue in the US and Western countries. The leading cause of death is heart failure (HF). Almost 5.5 million patients are diagnosed with congestive HF in the U.S and the majorcause of HF is myocardial ischemic disease. Therefore, improvement of therapy for post myocardial infarction (post-MI) HF is extremely important, and the development of a new class of medicine which prevents progression of HF would have a large market opportunity and represent a significant clinical advance. The ultimate goal of this project is to develop a new drug for heart failure (HF) by inhibiting type 5 adenylyl cyclase (AC5). Recently our studies demonstrated that inhibition of AC5 would be a strategy for treating HF. Disruption of AC5 gene in mouse prolongs lifespan by attenuating aging-related HF, protects against HF induced by chronic pressure overload, by excessive sympathetic stimulation and by myocardial ischemia, suggesting that an AC5 inhibitor would be a new class of HF drug. The phase I study will provide definitive evidence that a novel AC5 inhibitor has beneficial effect on post-MI HF in a small animal model. In our preliminary screening for AC5 inhibitors, adenine 9-D-arabinofuranoside (AraAde, also known as Vidarabine or Vira-A(R)), which was used in the clinic for a different indication, showed protection against HF in mice, suggesting a possible clinical utility of AC5 inhibitors for treating HF. In the presen application we will validate the effect of a novel AC5 inhibitor, PMC-6, on post-MI HF by using a mouse HF model. In the Phase II, we will further investigate the effect of PMC-6 on post-MI HF in a large animal model. Additionally, we will develop second generation PMC-6-type drugs with improved potency, better specificity and minimal adverse effects. We will evaluate the pharmacokinetics, drug metabolism, and safety of the most promising second generation AC5 inhibitor to enter into clinical trials. PUBLIC HEALTH RELEVANCE: Almost 5.5 million patients are diagnosed with congestive HF in the U.S and the major cause of HF is myocardial ischemic disease; however, no effective therapy has been established to treat congestive HF. The current investigation is aiming at generating a new class of medicine preventing progression of HF, which should have a large market opportunity and significant clinical importance.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government